Semagacestat是一种γ-分泌酶抑制剂,作用于Aβ42, Aβ40和Aβ38时,IC50分别为10.9 nM, 12.1 nM和12.0 nM,也抑制Notch信号通路,IC50为14.1 nM。
Semagacestat (LY450139) is a γ-secretase blocker for Aβ42, Aβ40 and Aβ38 with IC50 of 10.9 nM, 12.1 nM and 12.0 nM, also inhibits Notch signaling with IC50 of 14.1 nM in H4 human glioma cell. Phase 3.
10 μM 左右
~30 mg/kg 口服处理,每天一次
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Mitani Y, et al. J Neurosci, 2012, 32(6), 2037-2050.
[2] Elvang AB, et al. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo. J Neurochem. 2009 Sep;110(5):1377-87.
分子式 C19H27N3O4 |
分子量 361.44 |
CAS号 425386-60-3 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 70 mg/mL |
Water <1 mg/mL |
Ethanol 40 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT01035138 | Alzheimer's Disease | Drug: semagacestat | Eli Lilly and Company | Phase 3 | 2009-12-01 | 2014-09-22 |
NCT00762411 | Alzheimer's Disease | Drug: LY450139|Drug: Placebo | Eli Lilly and Company | Phase 3 | 2008-09-01 | 2015-01-28 |
NCT00594568 | Alzheimer's Disease | Drug: LY450139|Drug: Placebo | Eli Lilly and Company | Phase 3 | 2008-03-01 | 2015-03-13 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们